Regulatory Intelligence & Strategy
Regulatory Intelligence & Monitoring
Global regulatory monitoring, change impact assessments and inspection trend analysis — ensuring your organisation knows what regulators expect before inspectors arrive.
Executive Overview
The pharmaceutical and medical device regulatory environment changes at a pace that most quality and regulatory teams struggle to monitor systematically. EMA publishes revised guidelines, FDA issues new guidance documents and warning letter analysis reveals enforcement priorities that are not yet reflected in formal guidance. ICH guidelines move through multiple stages of development, MHRA diverges from EU positions and CDSCO revises Schedule M requirements. Each of these changes carries compliance implications that must be assessed and actioned before they become inspection findings.
Regulatory intelligence transforms reactive compliance — discovering gaps during inspections — into proactive compliance, where organisations anticipate regulatory expectations and maintain current alignment. The difference is significant: organisations with effective regulatory intelligence programmes spend less on remediation, experience fewer inspection observations and make better strategic decisions about quality system investments.
Sthira Assure provides structured regulatory intelligence services covering major international regulatory authorities, with analysis tailored to your specific regulatory markets, product portfolio and operational context. Our intelligence outputs are designed for use by Quality Directors, Regulatory Affairs Leaders and Compliance Managers who need actionable analysis, not raw regulatory text.
Authorities Monitored
- EMA (European Medicines Agency)
- FDA (US)
- MHRA (UK)
- CDSCO (India)
- Health Canada
- TGA (Australia)
- WHO & PIC/S
Discuss Intelligence Requirements
Speak with our team about your regulatory monitoring needs.
Request a ConsultationCommon Compliance Risks
Discovering Compliance Gaps on Inspection
Regulatory guidance changes constantly. New ICH guidelines, revised GMP annexes, updated FDA guidance documents and evolving MHRA post-Brexit positions all create compliance obligations that organisations must identify, assess and action. Those without systematic monitoring processes regularly discover compliance gaps for the first time during regulatory inspections — when the cost of remediation is highest and the regulatory pressure is greatest.
Unmanaged Impact of Regulatory Change
Even when organisations track regulatory publications, many lack systematic processes for assessing the specific impact on their operations, products and quality systems. A new guidance document may affect manufacturing procedures, analytical methods, supplier qualification requirements, documentation practices or regulatory submissions — and different areas of the organisation may need to respond differently. Without coordinated impact assessment, organisations respond in fragments or miss obligations entirely.
Inspection Trends as Leading Indicators
Regulatory authority inspection reports, warning letters, EMA Article 31 referrals and MHRA GMP deficiency letters are among the most valuable intelligence available to quality and regulatory professionals. They reveal current enforcement priorities, emerging compliance themes and specific technical expectations before they appear in formal guidance. Organisations that systematically analyse inspection intelligence are rarely surprised by what inspectors focus on.
Post-Brexit MHRA Divergence
The MHRA is increasingly diverging from EU regulatory positions across areas including clinical trials, good manufacturing practice, medical devices and pharmacovigilance. Organisations that continue to treat MHRA and EMA requirements as equivalent risk accumulating compliance gaps in the UK market. Systematic monitoring of MHRA divergence, and its impact on specific operational areas, is now a distinct regulatory intelligence requirement.
Scope of Services
Typical Deliverables
Frequently Asked Questions
What is regulatory intelligence and why does it matter?
Regulatory intelligence is the systematic monitoring, analysis and interpretation of regulatory authority outputs — guidance documents, inspection findings, enforcement actions, consultation papers and policy statements — to inform an organisation's compliance posture and strategic decisions. Organisations that invest in regulatory intelligence anticipate regulatory change; those that do not react to it after the fact, usually at higher cost and under greater pressure.
Which regulatory authorities do you monitor?
Our standard monitoring covers EMA, FDA, MHRA, CDSCO, Health Canada, TGA (Australia), WHO and key PIC/S member authorities. We also monitor ICH guideline development, relevant European Parliament and Council legislative activity, and major industry body guidance from ISPE, PDA, EFpia and equivalent organisations. Monitoring scope can be customised based on an organisation's specific market footprint.
How is regulatory intelligence delivered?
Regulatory intelligence can be delivered as a standalone subscription service providing curated monthly briefings, as a component of a broader managed services engagement, or as project-based impact assessments triggered by specific regulatory events. Briefings are tailored to the recipient organisation's specific regulatory environment, product portfolio and operational scope — not generic newsletters.
Can you analyse FDA warning letters relevant to our operations?
Yes. FDA warning letter analysis is one of the most practical forms of regulatory intelligence for quality teams. We analyse warning letters relevant to your sector, manufacturing operations and quality system design, extracting the specific compliance expectations that inspectors are currently enforcing, the typical remediation responses that regulators find acceptable and the operational changes most commonly required. This analysis directly informs inspection readiness activities.
Stay Ahead of Regulatory Change
Contact our team to discuss your regulatory monitoring requirements and the intelligence programme your organisation needs to remain inspection-ready.